Blogger

Should pharmaceutical employees be allowed to lecture about their products?

I am seeing a very strong trend of allowing pharmaceutical employees to speak to clinician and patient groups about their products in lectures set up by industry. I have attended many CME based and non CME lectures and I can say that I have hardly seen a neutral or unbiased lecture when a pharma employee …

Should pharmaceutical employees be allowed to lecture about their products? Read More »

Be Aware of TMC 125 (Etravirine, Tibotec new non nucleoside) limitations

If you are thinking about obtaining TMC 125 (Etravirine, a new non nucleoside yet to be approved) via Tibotec’s expanded access program (EAP) and you have developed resistance to non nucleosides in the past (Sustiva, Viramune, Rescriptor), be aware that it is very difficult to know if TMC 125 will work for your virus since …

Be Aware of TMC 125 (Etravirine, Tibotec new non nucleoside) limitations Read More »

The End of Nandrolone ?

The End of Nandrolone Nelson Vergel, Program for Wellness Restoration https://www.gmhc.org/health/treatment/ti/ti21_1.html The current terrain for wasting patients in the era of HAART On March 20, 2007, Watson Laboratories stopped the production of nandrolone decanoate (old brand name: Deca Durabolin), a low-cost injectable anabolic steroid used for HIV wasting, citing the lack of raw-material suppliers for …

The End of Nandrolone ? Read More »

TITAN and DUET Studies from Tibotec- Commentaries in the Lancet

TITAN & DUET Studies COMMENTARY No patient left behind-better treatments for resistant HIV infection The Lancet July 7, 2007 Bernard Hirschel a and Thomas Perneger ba. Division of Infectious Diseases, Geneva University Hospital, Geneva 1211, Switzerlandb. Clinical Epidemiology Service, Geneva University Hospital, Geneva, Switzerland Darunavir (TMC114) is a protease inhibitor specifically designed for “resistance to …

TITAN and DUET Studies from Tibotec- Commentaries in the Lancet Read More »

Call for Improving System of Patient Access to Investigational Drugs

I was part of this meeting and was very happy with the outcome. I hope the FDA and pharma listen to us. Representatives from the FDA, industry (Merck, Pfizer, Tibotec, Panacos and BI) , physician groups, Kaiser Permanente, researchers, and others were part of the discussion. **************************************HIV Research Group Calls for Improving System of Patient …

Call for Improving System of Patient Access to Investigational Drugs Read More »

Anal Cancer- Can it be prevented? Lecture in Houston this Thurs June 21

Rates of anal cancer among gay and bisexual men are 35 times greater than the general population HIV+ men and women are 80 times more likely to have anal cancer. THE GOOD NEWS IS THAT ANAL CANCER IS POTENTIALLY PREVENTABLE AND HIGHLY CURABLE. Come to hear Houston’s Dr. Eric Haas speak about ways to detect …

Anal Cancer- Can it be prevented? Lecture in Houston this Thurs June 21 Read More »

NEW HIV DRUGS AND THEIR STUDIES- COMMENTS FROM RESPECTED DOCTORS

THIS GREAT INFORMATION WAS PROVIDED BY CLINICAL CARE OPTIONS. THESE ARE COMMENTS ABOUT CLINICAL STUDY DESIGN ISSUES THAT I FOLLOW VERY CLOSELY AS AN ACTIVIST. IT IS VERY INTERESTING TO ME HOW SOME COMPANIES CHOSE TO SHOW THEIR DATA AND HURRY THEIR STUDY ENROLLMENT AT THE EXPENSE OF PATIENT VOLUNTEERS. THE NEXT HIV DRUG TO …

NEW HIV DRUGS AND THEIR STUDIES- COMMENTS FROM RESPECTED DOCTORS Read More »